Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease

[1]  Sheng-Yang M. Goh,et al.  Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve , 2021, Alzheimer's & Dementia.

[2]  J. Kulisevsky,et al.  In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. , 2021, Parkinsonism & related disorders.

[3]  J. Kulisevsky,et al.  Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease. , 2021, Parkinsonism & related disorders.

[4]  S. Salloway,et al.  Biphasic cortical macro‐ and microstructural changes in autosomal dominant Alzheimer's disease , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  N. Bohnen,et al.  Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[6]  Haijun Li,et al.  Role of homocysteine in the development and progression of Parkinson’s disease , 2020, Annals of clinical and translational neurology.

[7]  Qian Zhang,et al.  Gender- and age-related differences in homocysteine concentration: a cross-sectional study of the general population of China , 2020, Scientific Reports.

[8]  J. Kulisevsky,et al.  Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. , 2020, Parkinsonism & related disorders.

[9]  J. Kulisevsky,et al.  Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. , 2019, Parkinsonism & related disorders.

[10]  J. Kulisevsky,et al.  Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease , 2019, American Journal of Neuroradiology.

[11]  J. Kulisevsky,et al.  A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment , 2019, Human brain mapping.

[12]  L. Tan,et al.  Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta‐analysis of prospective cohort studies , 2019, Movement disorders : official journal of the Movement Disorder Society.

[13]  F. Mastaglia,et al.  Elevated Serum Homocysteine Levels Have Differential Gender-Specific Associations with Motor and Cognitive States in Parkinson's Disease , 2019, Parkinson's disease.

[14]  M. Gorno-Tempini,et al.  Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy , 2019, Brain : a journal of neurology.

[15]  J. Kulisevsky,et al.  Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease , 2019, Neurobiology of Disease.

[16]  D. Burn,et al.  Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson’s Disease , 2019, Journal of Parkinson's disease.

[17]  Daniel Weintraub,et al.  Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review , 2019, Movement disorders : official journal of the Movement Disorder Society.

[18]  Cheng Gu,et al.  Relationship between serum homocysteine level and cognitive impairment in patients with Parkinson‘s disease , 2019, Pteridines.

[19]  C. Davatzikos,et al.  Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease , 2018, European journal of neurology.

[20]  O. Monchi,et al.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson’s Disease: What Do Clinical and Neuroimaging Studies Tell Us? , 2018, Current Neurology and Neuroscience Reports.

[21]  O. Pasternak,et al.  Cortical microstructural changes along the Alzheimer's disease continuum , 2018, Alzheimer's & Dementia.

[22]  T. Montine,et al.  Homocysteine and cognitive function in Parkinson's disease. , 2017, Parkinsonism & related disorders.

[23]  R. Dixon,et al.  Profiling novel metabolic biomarkers for Parkinson's disease using in‐depth metabolomic analysis , 2017, Movement disorders : official journal of the Movement Disorder Society.

[24]  Marios Politis,et al.  Cognitive decline in Parkinson disease , 2017, Nature Reviews Neurology.

[25]  B. MacIntosh,et al.  Summative effects of vascular risk factors on cortical thickness in mild cognitive impairment , 2016, Neurobiology of Aging.

[26]  J. Kulisevsky,et al.  COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression , 2016, BMC Neurology.

[27]  D. Berg,et al.  Vascular Risk Factors and Cognition in Parkinson's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[28]  K. Chaudhuri,et al.  The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[29]  Angie A. Kehagia,et al.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.

[30]  Xiqun Chen,et al.  Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. , 2010, Biomarkers in medicine.

[31]  P. Barone,et al.  Neurotransmission in Parkinson’s disease: beyond dopamine , 2010, European journal of neurology.

[32]  M. Ciaccio,et al.  Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. , 2010, Current clinical pharmacology.

[33]  Thomas Foltynie,et al.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.

[34]  Nikolaus Weiskopf,et al.  A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging , 2009, NeuroImage.

[35]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[36]  R. Diaz-Arrastia,et al.  Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. , 2003, Archives of neurology.

[37]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.